Novel starch-based scaffolds for bone tissue engineering : cytotoxicity, cell culture, and protein expression by Salgado, A. J. et al.
465
INTRODUCTION
EVERY YEAR millions of people worldwide suffer fromunrecoverable bone lesions such as severe bone frac-
tures or bone ablations due to tumor extraction or to trau-
matic injuries.1,2 The repair of these lesions is a great
challenge to reconstructive surgery that has not yet been
properly addressed. In fact, current treatments are com-
monly based on the use of autologous bone for the re-
construction of such lesions.3 However, this technique
has several limitations such as the limited supply of suit-
able bone, the pain inflicted on the patient to obtain the
explant, the risk of infection, hemorrhage, cosmetic dis-
ability, nerve damage, and loss of function among oth-
ers.3–5 However, and despite the fact that materials sci-
ence technology has resulted in clear improvements in
the field of bone substitution medicine, no adequate bone
substitute has been developed to date.
In the last decade of the 20th century special empha-
sis was put on an emerging field of science called tissue
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ABSTRACT
Starch-based biomaterials and scaffolds have been proposed for several biomedical applications. In
the present work new scaffolds based on a 50/50 (wt%) blend of corn starch/ethylene-vinyl alcohol
(SEVA-C) were studied. These scaffolds were processed by a melt-based technology, which has been
used before with other starch-based materials but never with SEVA-C. Scanning electron microscopy
(SEM) observation showed that the developed porous structures were 60% porous with pore size
between 200 and 900 mm and a reasonable degree of interconnectivity. Moreover, scaffolds pre-
sented a compressive modulus of 117.506 3.7 MPa and a compressive strength of 20.86 2.4 MPa.
Cytotoxicity evaluation was performed according to ISO/EN 10993 part 5 guidelines, and revealed
that the developed scaffolds were nontoxic and did not inhibit cell growth. Direct contact assays
were also carried out by use of a cell line of human osteoblast-like cells (SaOS-2). Cells were seeded
(3 3 105 per scaffold) and allowed to grow for 4 weeks at 37°C, in a humidified atmosphere con-
taining 5% CO2. Total protein assay showed that the cells were able to grow for the 4 weeks of the
experiment. These data were further confirmed by SEM. Moreover, a cell viability assay (MTS test)
demonstrated that cells were perfectly viable after the 4 weeks of culture, showing the adequacy of
the developed structure in supporting them. Finally, Western blot analysis revealed that osteopon-
tin was being actively expressed by the cells, which, in association with collagen deposition observed
by SEM, seems to indicate that bone extracellular matrix was being deposited. Consequently it is
believed that starch-based scaffolds should be considered as an alternative for bone tissue-
engineering applications in the near future.
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engineering, which combines state of the art materials
science with concepts from life sciences.6 Its main pur-
poses are the production of tissues and organ substi-
tutes/equivalents that can replace or restore the natural
features and physiological functions of natural tissues in
vivo.6,7 In this field it is believed that most of the pri-
mary cells isolated from organs or tissues are anchorage
dependent. Therefore, the presence of a supporting ma-
terial (scaffolds) that can act as a template for cell growth
is essential.7 These scaffolds should not only possess an
adequate surface chemistry, allowing cell attachment 
and proliferation, but should also be biocompatible,
biodegradable, and porous, in order to allow vascular-
ization and mass transfer to occur where needed. Finally,
the scaffolds should exhibit adequate mechanical prop-
erties so that the integrity of the neotissue/neorgan can
be assured.7–10 In the case of bone tissue engineering the
latter are of the utmost importance because (1) due to
bone characteristics, high rates of mass transfer are ex-
pected to occur, even under in vitro culture conditions,
and (2) when implanted in vivo, high rates of vascular-
ization should occur.11 Moreover, bone is always under
continuous stress and hence the mechanical properties of
the implanted construct should ideally match those of 
living bone and must maintain it mechanical stability 
until the neotissue can assure its mechanical role by 
itself. At this stage, the scaffold is no longer needed and
should be, or in the process of being, completely de-
graded.
Up to now several materials, from ceramics to natural
polymers, as well as processing techniques have been
used to develop scaffolds for bone tissue engineering.7,12
For instance, bone regeneration has been partially
achieved by using coral,3,13 hydroxyapatite (HA) or 
tricalcium phosphate (TCP) based scaffolds.14–16 In other
cases aliphatic polyesters, such as polyglycolic acid
(PGA), polylactic acid (PLA), and poly(e-caprolactone),
or their copolymers have been used.12,17–19 However, and
in spite of the fact that relatively good results were ob-
tained with these materials, they display some problems
such as a lack of mechanical stability and brittle nature,
in the case of ceramics,7 or the release of acidic degra-
dation products that can adversely affect biocompatibil-
ity in the case of aliphatic polyesters.7,20
As a result, new materials that can be an alternative to
those currently used in tissue engineering have been de-
veloped. For instance, starch-based thermoplastics have
been put forward as candidates for potential biomedical
applications, namely as partially degradable bone ce-
ments20 to be used, drug delivery carriers and hydro-
gels,21,22 and in the bone fixation/filling of bone defects
in the orthopedic field.23 Their use as scaffolds for tis-
sue engineering was also considered, and recent studies
revealed that they had adequate mechanical and degra-
dation properties.9,24 As previously described their degra-
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dation is characterized by a weight loss of about 15–20%
in the first 15 days, after which the materials slowly de-
grade by chemical attack.9,20 Further information on ma-
terials degradation mechanisms can be found elsewhere.9
It was also found that they are able to support cellular
growth.8 Furthermore, previous in vivo studies have also
shown that these materials not only do not cause any ma-
jor inflammatory response, but also exhibit bone-bond-
ing behavior when reinforced with bioactive ceramics.25
The present study reports on the morphology, mechan-
ical properties, cytocompatibility, cell proliferation, and
protein expression of human osteoblast-like cells on novel
scaffolds based on a blend of starch with ethylene-vinyl al-
cohol (SEVA-C), processed by a previously described tech-
nique.9 This processing is based on extrusion of the raw
polymeric material with a certain percentage of nontoxic
blowing agents. Results have shown that the developed
scaffolds have adequate mechanical properties. Further-
more, they also support the growth of human osteoblast-
like cells on their surface and inner regions, with what
seemed to be consequent extracellular matrix deposition.
MATERIALS AND METHODS
Scaffold production
The polymer used in the present study was a 50:50 (wt%)
blend of corn starch/ethylene-vinyl alcohol (SEVA-C; No-
vamont, Novara, Italy). Scaffolds were obtained by using
a methodology based on extrusion with blowing agents, as
previously described by Gomes et al.9 Briefly, the polymer
was previously mixed with 1% (wt%) of a solid blowing
agent based on citric acid (trade name BIH40; Clariant,
Muttenz, Switzerland) in a biaxial rotating drum. This mix-
ture was then extruded in a Carvex twin-screw extruder
with a 12-mm die, after which the resulting materials were
cut into 53 53 5 mm3 samples.
Scaffold characterization
Pore morphology, namely size, distribution, and inter-
connectivity, was characterized by scanning electron mi-
croscopy (SEM), with a Leica Cambridge S360 (Leica
Cambridge, Cambridge, UK). All samples were previ-
ously sputter coated with gold (JFC-1100; JEOL, Tokyo,
Japan). Pore size measurements were obtained from five
micrographs, obtained from six different samples (five
micrographs per sample) acquired in the SEM. Pore size
was then determined by making the average of several
diagonal measurements from the pores, using image anal-
ysis software.
Porosity was calculated as follows: (1) weight and vol-
ume of each sample (n 5 6) were determined; (2) from
these measurements, the apparent density of the scaffolds
was calculated; and (3) the scaffold porosity was obtained
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on the basis of the following formula: porosity (%) 5 e 5
1 2 r*/r 3 100 (rSEVA-C 5 1.28, r* 2 apparent density).
Mechanical properties of the developed scaffolds were
assessed in compressive experiments with an Instron
4505 universal testing machine (Instron, Canton, MA) us-
ing a load cell of 50 kN. Samples (n 5 6) were previ-
ously cut in cylinders with a diameter of 1.5 cm and a
height of 1 cm. The compression tests were carried out
at a cross-head speed of 2 mm/min (4.73 1025 m/s) un-
til fracture, or until obtaining a maximum reduction in
sample height of 60%.
In vitro cytotoxicity assessment
In all cytoxicity tests performed, latex rubber (Velos-
Perforex, Manchester, UK) and standard culture medium
were used as positive and negative controls, respectively.
Latex rubber is known to have a strong cytotoxic effect
leading to extensive cell death and lysis, and is commonly
used as a positive control for cell death. To assess the
short-term cytotoxicity of the developed scaffolds, the
following ISO/EN 10993 part 5 guidelines were used26:
MEM extraction and MTS, both with a 24 h extraction
period. These assays are particularly aimed at establish-
ing the possible toxic effects of leachables released from
medical polymers during extraction. The objectives of the
MEM extraction test are to evaluate changes in cell mor-
phology and growth inhibition, whereas the MTS test de-
termines whether cells are metabolically active.
Cell culture. The present experiment used a cell line
of rat lung fibroblasts—L929, obtained from the Euro-
pean Collection of Cell Cultures (ECACC). Cells were
grown as monolayers in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma, St. Louis, MO) supplemented
with 10% fetal bovine serum (FBS; Biochrom, Berlin,
Germany) and 1% of an antibiotic–antimycotic mixture
(1%; Sigma), and trypsinized before the experiments. For
the MEM extraction tests, cells were seeded in 24 well
plates, at a density of 1.253 105 cells per well (n 5 3).
For the MTS test, cells were seeded in 96 well plates
(n 5 6), at a density of 2 3 104 cells per well. In both
cases cells were incubated for 24 h at 37°C, in a humid-
ified atmosphere containing 5% CO2.
MEM extraction test. In all tests the ratio of material
weight to extract fluid was constant and equal to 0.2 g/mL
for porous samples, whereas for the positive control the
ratio of material outer surface to extraction fluid was 2.5
cm2/mL. Test material (n 5 6) and positive control were
extracted for 24 h at 37°C, using complete culture
medium as the extraction fluid. Before the tests, culture
medium was removed from the wells and an identical
volume, 2 mL, of extraction fluid was added. Cell re-
sponse was evaluated after 24, 48, and 72 h of incuba-
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tion time. Parameters analyzed included confluence of
the monolayer, degree of floating cells, and changes in
morphology. After 72 h the percentage of growth inhibi-
tion was determined by cell counting with a hemocy-
tometer and trypan blue exclusion method. Final mea-
surements were then corrected for the negative control.
MTS test. CellTiter 96 One solution Cell Proliferation
Assay kit (Promega, Madison, WI) is based on bioreduc-
tion of the substrate, 3-(4,5-dimethylthiazol-2-yl)-5(3-car-
boxymethoxyphenyl)-2(4-sulfofenyl)-2H-tetrazolium
(MTS), into a brown formazan product by dehydroge-
nase enzymes in metabolically active cells27,28 and is
commonly used for cell viability evaluation.8 The ex-
traction procedure was the one described above for the
MEM test, using 200 mL of extraction fluid per well. Af-
ter 72 h the extraction fluid was removed and 200 mL of
a mixture, containing serum-free cell culture medium
without phenol red, and MTS, was added to each well.
Cells were then incubated for 3 h at 37°C in a humidi-
fied atmosphere containing 5% CO2. At this time optical
density (OD) was measured with a plate reader (Molec-
ular Devices, Sunnyvale, CA) at 490 nm. The mean OD
value obtained for the negative control was standardized
as 0% metabolic inhibition.
Direct contact assays
Cell seeding on starch-based scaffolds. Human os-
teosarcoma cells (SaOS-2 cell line; ECACC) were grown
as monolayer cultures in DMEM supplemented with
10% FBS, 1% antibiotic–antimycotic mixture, 5 mM b-
glycerophosphate (Sigma), and 50 mM ascorbic acid
(Sigma) until they reached the P10 (passage 10) stage.
At that time cells were trypsinized, centrifuged, and re-
suspended in cell culture medium. Aliquots (20 mL) con-
taining 3 3 105 cells were then seeded on top of the
porous structures, which had been previously placed in
24 well culture trays. Two hours after cell seeding, 1 mL
of culture medium was added to each well and cell–scaf-
fold constructs were incubated for 4 weeks in a humidi-
fied atmosphere at 37°C, containing 5% CO2, with
medium changes every 3 to 4 days. On the last week of
the experiment, and in order to stimulate the mineraliza-
tion of the extracellular matrix (ECM), dexamethasone
(Sigma) was added to the culture medium in a final con-
centration of 1028 M.
Cell proliferation. Cell proliferation of human osteo-
blast-like cells on starch-based scaffolds was assessed by
the Sedmak total protein assay. Twelve hours and 7, 14,
21, and 28 days after seeding, cell–scaffold constructs
(n 5 6) were washed in 0.15 M phosphate-buffered saline
(PBS), lysed in 750 mL of lysis buffer (20 mM Tris, 1
mM EDTA, 150 mM NaCl, and 1% Triton X-100) sup-
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plemented with 100 mM phenylmethylsulfonyl fluoride
(PMSF; Sigma) and a cocktail of protease inhibitors (chy-
mostatin, leupeptin, antipain, and pepstatin) at a final con-
centration of 1 mg/mL, and finally sonicated three times
at 40 kV (15 s each). After sonication scaffolds were re-
moved and the resulting suspension was centrifuged for
10 min at 14,000 rpm and 4°C at the end of which the
pellet was discarded. Scaffolds without cells but kept un-
der the same culture conditions were used as blanks. For
protein quantification 20 mL of the protein extract was
removed and added to 2 mL of Sedmak reagent (0.06%
Coomassie blue in 0.3 M HClO4) previously diluted in
0.1 N HClO4 in a 1.5:3.5 ratio. The reaction was allowed
to occur for 10 min, at the end of which absorbance was
measured at 620 nm. The results were then plotted against
a standard curve made with bovine serum albumin (BSA)
ranging from 0 to 25 mg. Total protein was then calcu-
lated by extrapolation for the 750 mL of protein extract
solution.
Cell viability assay. Cell viability was assessed after
12 h and 7, 14, 21, and 28 days by using the MTS test
as described previously.8 Briefly, cell–scaffold constructs
(n 5 6) were washed in 0.15 M PBS and placed in a mix-
ture containing serum-free cell culture medium and MTS
at a 5:1 ratio and incubated for 3 h at 37°C in a humid-
ified atmosphere containing 5% CO2, at the end of which
100 mL (n 5 6) was transferred to 96 well plates and the
OD determined at 490 nm.
Cell adhesion to SEVA-C scaffolds. The adhesion of
human osteoblast-like cells to SEVA-C scaffolds was as-
sessed weekly by SEM. To determine whether cells were
growing in a three-dimensional manner into the inner re-
gions of the scaffolds, the latter were cut into portions of
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equal size and then observed under the SEM. For that,
cell–scaffold constructs were washed in 0.15 M PBS and
fixed in 2.5% glutaraldehyde in PBS. Afterward, the con-
structs were washed again in PBS, subjected twice to a
50, 70, 90, and 100% ethanol series (15 min each), and
finally air dried. Samples were then sputter coated with
gold (JEOL JFC-1100) and analyzed with a Leica Cam-
bridge S360 scanning electron microscope.
Western immunoblot analysis. For Western blot anal-
ysis, protein was extracted weekly and quantified as de-
scribed above (see Cell Proliferation). Aliquots contain-
ing equal amounts of protein (20 mg) were then loaded
into a 4% stacking polyacrylamide gel and a 10% run-
ning gel, subjected to electrophoresis, and electrotrans-
ferred to a Hybond P membrane (Amersham Biosciences,
Piscataway, NJ). Membranes were saturated with 5%
(w/v) fat-free dry milk in TBS-T (50 mM Tris, 150 mM
NaCl, 0.1% Tween 20, pH 7.6) for 1 h and 45 min at
room temperature. Blots were then further incubated for
1 h, at room temperature, with primary antibody against
osteopontin (University of Iowa, Iowa City, IA) at a 1:200
dilution. After washing with 1% milk–TBS-T solution,
blots were further incubated for 1 h with anti-mouse IgG
antibody coupled to horseradish peroxidase (Amersham
Biosciences). The immune complex was detected by in-
cubation with the ECL system (Amersham Biosciences)
and visualized by chemiluminescence.
Statistics
Statistical evaluation was performed using two-tailed
paired Student t tests, to assess the statistical differences
between groups at different time points. Statistical sig-
nificance was defined as p , 0.05 for a 95% confidence
interval.
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FIG. 1. (a) SEVA-C scaffold obtained by extrusion with blowing agents, presenting 60% porosity and a pore size of 200 to
900 mm; (b) microporosity with pore size ranging from 2 to 20 mm.
a) b)
RESULTS AND DISCUSSION
Scaffold characterization
The porous structure of the scaffolds results from the
decomposition of the blowing agent when heated during
the extrusion process. When decomposing, the blowing
agent releases CO2 and H2O, which will create the pores
within the polymeric matrix. Previous studies have shown
that by using this technology it was possible to produce
scaffolds with an adequate pore size and distribution and
also excellent mechanical properties.9
In the present work, the structure of the porous scaf-
folds (Fig. 1a) consisted of a reasonably interconnected
network of pores with 50 to 60% porosity, presenting
a pore size between 200 and 900 mm. This pore size is
believed to be ideal for bone tissue engineering.29 Mi-
cro-pores, with size ranging from 2 to 20 mm, were also
found (Fig. 1b), making these scaffolds also suitable
for the in-growth of capillary vessels, which are always
important for gaseous exchange and nutrient delivery
to the cells. Many other scaffolds do not allow for
proper vascularization as they do not have appropriate
micropores.
Samples exhibited a compressive modulus of 117.56
3.7 MPa and a compressive strength of 20.8 6 2.43 MPa.
These values are similar to those found in the literature
for trabecular bone.30 This means that, from a mechani-
cal point of view, the tested samples have properties that
make them suitable for use in bone tissue engineering.
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In vitro cytotoxicity assessment
Regarding the short-term MEM extraction tests, there
was no growth inhibition detected after 72 h (0.06 0.0%)
when using the trypan blue exclusion method. In all tests,
the negative control did not affect cell proliferation and
morphology: a monolayer of normally spread cells could
be observed (Fig. 2a). However, the toxic effect of the
positive control was clear: cells exhibited severe mor-
phological changes and they were not able to proliferate
(Fig. 2b). The tested material, porous SEVA-C scaffolds,
did not demonstrate any cytotoxic effect. The extract did
not have any effect on L929 cell morphology and pro-
liferation. Under these conditions the cells displayed mor-
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a) c)
b)
FIG. 2. L929 cells incubated with (a) negative control, (b)
positive control, and (c) SEVA-C scaffolds, extracts over a 
72-h period (original magnification, 3100).
FIG. 3. MTS reduction by L929 cells after incubation with
the test and positive control extracts over a period of 72 h. Re-
sults are based on optical density measurements and were nor-
malized for the negative control.
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on its surface, of proteins from cell culture medium
serum.31 This film of proteins acts in vitro like the ma-
trix synthesized in vivo by bone-forming cells and its na-
ture, extent, and stability are to a large extent determined
by the surface properties of the material and are thus a
reflection of the characteristics of the substrate.31,32
Regarding the present experiment, SEM observation
allowed to determine that osteoblast-like cells were well
adhered to SEVA-C based scaffolds after 1 week in cul-
ture (Fig. 4a). Cells adhered mainly to the bars of the
scaffolds, while at the same time being able to span across
pores. This observation demonstrated the adequacy of the
pore size range within the SEVA-C scaffold (Fig. 4a).
Furthermore, an observation made of the scaffold inner
regions (Fig. 4b), as referred to in Materials and Meth-
ods, revealed that cells were also capable of colonizing
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a) c)
FIG. 4. Scanning electron microscopy (SEM) of SaOS-2 cell adhesion and proliferation on SEVA-C-based scaffolds after (a
and b) 1 week, (c and d) 2 weeks, (e and f) 3 weeks, and (g and h) 4 weeks. (b, d, f, and h) Inner regions of the scaffolds, as
explained in Materials and Methods. As shown, growth was sequential and, after 1 week in which the cells filled most of the
bars of the scaffolds (a) and already some infiltration into the inner parts had occurred (b), cells started to colonize the inner re-
gions of the scaffolds, presenting massive colonization after 4 weeks in culture (g and h). Moreover, collagen fibril deposition
was observed, indicating the possible deposition of bone extracellular matrix (ECM; arrows) (d).
d)
phologies and proliferation patterns similar to those of
the negative control samples (Fig. 2c).
In the MTS test, L929 cells produced large amounts
of a brown formazan product after incubation with the
tested extract. This is an indicator of normal metabolism
(Fig. 3). This fact shows that cells were able to incorpo-
rate and metabolize MTS and hence their perfect viabil-
ity. Furthermore, MTS incorporation under these condi-
tions was similar to that of the negative control, which
supports our claims of lack of cytotoxic effects of the
tested scaffold material.
Direct contact assays
The mechanism that dominates initial cell attachment
to the surface of a biomaterial, in vitro, is the adsorption
these areas. As expected, this process was less evident
when compared with that occurring on the surface of the
scaffolds. By week 2 it was possible to observe a higher
degree of colonization both on the surface of the mater-
ial (Fig. 4c) and in the scaffold inner regions (Fig. 4d),
accompanied by what seems to be collagen production
by the cells (Fig. 4d). Finally, by the end of week 3 (Fig.
4e and f) and week 4 (Fig. 4g and h), osteoblast-like cells
had massively colonized the scaffolds, showing that these
were good substrates for cell adhesion and proliferation.
These results are not typical for biodegradable polymers
because of the continuous change of the surface and re-
lease of products due to polymer degradation. In addi-
tion, cells were able to enter the scaffold inner regions at
every time point (Fig. 4b, d, f, and h). This was an indi-
cation that the scaffolds had an adequate porosity for cell
migration, and also for three-dimensional cell growth
within the porous structures, which are requirements for
bone tissue-engineering applications.
Cell proliferation assay (Fig. 5) confirmed the SEM
observations, and demonstrated that cells were able to
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FIG. 4. Continued.
FIG. 5. Cell proliferation was assessed weekly by means of
a total protein assay. Cell density used was 3 3 105 cells per
scaffold. Cells were kept in culture for 4 weeks in complete
culture medium supplemented with 5 mM b-glycerophosphate,
and 50 mM ascorbic acid. On the last week of the experiment
dexamethasone was added to the culture medium for a final
concentration of 1028 M. (n 5 6; means6 SD; *p , 0.05.)
grow within the three-dimensional structure. Statistical
analysis showed that the growth was always significantly
different (p , 0.05) in the first 3 weeks of the experi-
ment, being higher during week 1 then in weeks 2 and
3. During week 4 of the experiment cell growth stopped,
and a slight decrease in the amount of total protein, which
was not significant (p . 0.05), was detected. These dif-
ferences occurred during cell growth into the porous
three-dimensional scaffolds and were expected. It is nat-
ural that cell growth is higher during the first week, be-
cause after a short initial period of adaptation to the new
substrate, the cells have an empty substrate available for
filling. It is clear that, after this initial period of growth
(week 1), during which the cells occupy most of the sur-
face of the three-dimensional porous structure, they will
have to find new areas to grow, and so they start to fill
the pores and to proliferate into the inner regions of the
scaffolds. Because these processes are more complex, the
cell growth rate diminishes, which is the reason for the
lower growth rate during weeks 2 and 3 of the experi-
ment. After this period of growth, the cells occupy most
of the scaffold matrix, and cell growth stops because,
once cells reach confluence, cell growth rates are identi-
cal to cellular death rates. This is why during week 4 of
the experiment there was an arrest in net cell growth. This
kind of behavior has already been reported in the litera-
ture.8,33 Moreover, this fact can also be explained by the
addition to the culture medium of dexamethasone, which
is a well-known stimulating factor of the osteogenic phe-
notype and at the same time decreases the rate of cellu-
lar growth.34,35
Regarding cellular viability, OD values for MTS in-
creased during week 1 (p , 0.05) and week 2 (p , 0.05)
of the experiment, being clear that cells were metaboli-
cally active (Fig. 6). However, the OD values showed a
slight decrease, which was not significant during week 3
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(p . 0.05) and week 4 (p . 0.05) of the experiment.
These decreases in OD values are related to both changes
in the metabolism of the cells, probably related to the ac-
tivation of certain pathways connected with extracellular
matrix production, and to the decrease and arrest of cel-
lular growth for the same time periods.
Protein expression
During the course of bone formation, osteoblasts pro-
duce a series of proteins that will make part of the bone
ECM, osteopontin being one of them.
In vivo, osteopontin is commonly found in specific re-
gions of bone such as cement lines in remodeling bone
and at laminae limitantes at bone surfaces; it is involved
in bone remodeling, cell adhesion, extracellular matrix
mineralization, and the linking between matrix and min-
eral, and it is produced by both osteoblasts and osteo-
clasts.36 In vitro, osteopontin is commonly associated
with the formation of a collagen-free cement layer on
which bone is subsequently deposited.36
Regarding the present experiment, Western blot anal-
ysis clearly revealed that osteopontin was being ex-
pressed by cells previously seeded on the scaffolds, dur-
ing the 4 weeks of the experiment (Fig. 7). This fact,
associated with the collagen deposition observed by SEM
(Fig. 4d), seems to indicate that active deposition of bone
extracellular matrix was happening as well as its proba-
ble mineralization.
CONCLUSIONS
With the present work it was possible to show that
scaffolds based on a 50:50 (wt%) blend of corn
starch/ethylene-vinyl alcohol (SEVA-C) present a range
of properties that are believed to be adequate for bone
tissue-engineering applications. Scaffolds were shown to
be noncytotoxic and clearly cytocompatible. Direct con-
tact assays revealed that human osteoblast-like cells were
able to grow both on its surface and into the inner parts
of the scaffolds. This fact clearly demonstrates that the
tested three-dimensional porous structures not only have
the right porosity, but also allow for three-dimensional
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FIG. 7. Western blot analysis of osteopontin expression by
SaOS-2 cells seeded on starch-based scaffolds. Protein expres-
sion was detected over 4 weeks (W1, W2, W3, and W4), indi-
cating the deposition of bone extracellular matrix (ECM).
FIG. 6. Cell viability was assessed weekly by the MTS test.
Cell density used was 3 3 105 cells per scaffold. Cells were
kept in culture for 4 weeks in complete culture medium sup-
plemented with 5 mM b-glycerophosphate (Sigma), 50 mM
ascorbic acid (Sigma). On the last week of the experiment dex-
amethasone was added to the culture medium for a final con-
centration of 1028 M. (n 5 6; means6 SD; *p , 0.05.)
growth of the cells. Finally, protein expression studies
associated with SEM observation seem to indicate that
bone extracellular matrix was being deposited.
Because of this combination of properties it is strongly
believed that the materials and scaffolds herein proposed
may be a quite valid alternative to the currently used ma-
terials when considering bone regeneration/engineering
applications in the near future.
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